Equine antisera to human adenovirus types 1 to 33 were prepared and evaluated by hemagglutination-inhibition and serum neutralization tests. Detailed data on the potency and purity of the immunizing antigens were tabulated as one means of evaluating the antisera. Most of the 52 hemagglutination-inhibition and 25 serum neutralization major or minor heterotypic responses among the equine antisera were observed at similar levels in previous studies with rabbit antisera and appeared to represent genuine antigenic relationships among the human adenoviruses. Equine antisera to human adenoviruses 1 to 33 and a similarly packaged normal horse serum served as lots of fully tested sera for definitive typing of isolates and as reference standards for evaluating other antisera.
The adenoviruses (AV) were first described in 1953 as cytopathic agents in tissue cultures of human adenoids (49) . As knowledge about them has grown, their importance in human disease has increasingly been recognized. Some AV serotypes, especially those of groups I and III and types 8 and 19 of group II (22, 45) , are associated with ocular, aural, oral, respiratory, enteric, urinary, or generalized disease conditions (1, 2, 5, 6, 9, 11, 12, 16, 17, 19, 26, 27, 32, 34, 35, 37-40, 42, 51, 54, 56, 57, 60 ; H. L. S. Knopf and J. C. Hierholzer, Amer. J. Ophthalmol., in press). Adenovirus infections account for some of the most severe illnesses in infants and children (5, 6, 8-11, 17, 21, 38-40, 55, 56, 60, 62, 63) , military trainees (15, 27, 30, 50, 61) , and, occasionally, adults (4, 13, 26, 32, 35, 42, 44, 56, 57, 60 ; Knopf and Hierholzer, in press).
As epidemiological, genetic, and biophysical knowledge of the adenoviruses has developed, new serotypes and antigenic hybrids have been described until the present number of 33 serotypes and an unknown number of complex intermediate strains have made serotyping an ambitious task. (Types 32 and 33 were officially accepted as new types at the London meeting of Directors of World Health Organization Respiratory Virus and Enterovirus Reference Centres, 16-19 April 1973 .) Yet, with the increasing association of adenoviruses with human illness, the positive identification of isolates is more important than ever. To facilitate typing of AV isolates and evaluation of independently prepared antisera, the Center for Disease Control has been producing reference antisera in horses since 1962 . The first 18 of these type-specific sera were described in an earlier report (36) . Antisera to all 33 currently accepted serotypes are described in the present report, and particular attention is given to heterologous reactions.
MATERIALS AND METHODS
Production of immunizing antigen (IA). Prototype strains of AV 1 to 33 (Table 1) were obtained from the American Type Culture Collection, Rockville, Md., or from the Research Resources Branch,of the National Institute of Allergy and Infectious Diseases, Bethesda, Md. The absence of mycoplasmas in the seed virus cultures was ensured by initially treating most strains with 20% diethyl ether for 18 h at 4 C, titrating to infectivity end points, and passaging from the highest dilution containing infectious virus. Stock viruses and IA were prepared for types 1 to 3 and 5 to 18 in KB cell cultures infected, harvested, and clarified as described by Lucas et al. (36) , and for types 4 and 19 to 33 in KB or HEp-2 cultures handled as described by Hierholzer et al. (25) . The working stocks and IAs were comprehensively tested for bacterial, fungal, and mycoplasmal sterility as previously described (25) , for contamination with other complete viruses by the serum neutralization breakthrough test (20, 23) , and for contamination with adeno-associated viruses (AAV), types 1 to 4, by type-specific complement fixation (CF) tests (31 (25) . Details of the inoculation sites for schedules no. 1 and 3 have been described (25) .
Upon completion of the immunization schedule, the horses were fasted for 24 to Packaging of antiserum. After the blood was stored for 3 h at 4 C, the clots were broken up and the serum was expressed from the macerated clots by adding lead weights for an overnight period at 4 C. The serum was collected by decanting and clarified by centrifugation at 10,000 rpm through an RC2-B Sorvall centrifuge equipped with a type KSB SzentGyorgi/Blum continuous-flow system with a twochannel distributor operating at an adjusted rate of 400 ml/min. The clarified product was filtered through 0.22-Mm membrane filters (Millipore Corp.) and tested for sterility as described above. The final product was dispensed in 2-ml volumes, frozen at -65 C, and lyophilized. for 48 h at ambient shelf temperature under a chamber vacuum of 20 to 30 ,m and a condenser temperature of -40 to -45 C.
Evaluation of antiserum. Sera were tested for type-specific HI and serum neutralization (SN) antibody levels throughout the immunization schedule and before and after lyophilization (25, 36) . Lyophilized equine antisera were reconstituted with sterile distilled water. All antisera were prepared as 1:10 starting dilutions in sterile PBS and absorbed with 0,1 ml of 50% rat red blood cell (RBC) suspension for HI tests with groups II and III adenoviruses and with 0.1 ml of 50% rhesus erythrocytes for HI tests with group I viruses (22, 29) . The sera were not heat inactivated or treated in any other way (25) . HI tests were performed by the standardized microtiter method, with 0.01 M PBS diluent or PBS modified with heterotypic serum as described above and with 4 HA units of antigen per 0.025 ml (29) . Rat and rhesus erythrocyte suspensions were standardized to 0.4% (28) . SN tests were performed by the 3-day test in primary rhesus monkey kidney (MK) cell cultures (25, 58 represents the inferred mode of at least five determinations carried out with different lots of buffer, RBC suspensions, and antigen dilutions to minimize the effect of any one reagent at one time (22, 29, 45) . This is particularly critical since variability in HI titers may be caused by variation of the HA titer of the test antigen under different conditions, even though the same antigen dose may always be used (29, 36, 45) . The variability normally observed in HI titers throughout five determinations was no more than plus or minus one dilution from the listed titer. Negative (titer <10) virus-serum reactions were tested at least twice. In instances where cross-reactions with rabbit antisera were reported by other investigators but no reaction was seen with the equine antisera, the tests were repeated five times with different reagents. Antisera to types 12, 18, and 31 contained no detectable homologous or heterologous HI titers when tested with either rat or rhesus erythrocytes in either PBS or heterotypic serum diluent. However, low-level HA activity in the lAs could be demonstrated with all three virus types.
Throughout the course of immunization, homologous and heterologous (including anticipated heterologous) HI titers were determined in parallel tests with unheated and heat-inactivated sera (56 C, 30 min). The titers were consistently identical. Also, homologous HI titers of antisera types 1 to 21 were determined in parallel tests with unheated sera, sera unheated but absorbed with 12.5% acid-washed kaolin (24 C, 20 min), and sera heat inactivated and absorbed with kaolin. Since serum controls, in all instances, did not reveal nonspecific inhibition, there was no need for serum treatment. Furthermore, titers in the kaolin-absorbed sera (heated or unheated) were generally one dilution lower than in the untreated sera.
The SN antibody titers of the equine antisera are shown in Table 3 . An SN titer is defined as the dilution factor of the highest dilution of antiserum causing a 2+ reduction in CPE from that observed in the working dilution (virus control) in 3 or 4 days (58) . Each of the homologous and heterologous titers listed is the inferred mode of at least three tests performed with different lots of MK tissue culture. Although the sensitivity of MK cells has been reported to vary considerably and thus influence the titer (36, 58) , little variability was observed in repeated tests in this study. Variation was never more than plus or minus one dilution from the listed titer. All negative (titer < 10) virus-serum reactions were tested twice.
SN homologous and selected heterologous titers were determined in parallel with unheated sera and with sera heat inactivated at 56 C for 30 min. No difference in SN titers was observed and in none of the 33 equine antisera were nonspecific inhibitors found. The 33 reference adenovirus antisera prepared in horses are complemented by normal horse serum (lot 2, 9-25-70), which like the antisera was lyophilized in 2-ml volumes. This control serum was obtained from a horse raised as the immunized horses were, but with no injections given. The lot 2 normal serum has been thoroughly tested and contains no measureable HI or SN antibodies to AV 1 to 33.
Most of the cross-reactions observed by HI (Table 4 ) and SN (Table 5 ) among the 33 serotypes were anticipated on the basis of published data with rabbit antisera (3, 18, 23, 24, 33, 41, 43, 45, 46-48, 53, 58, 59, 64, 66, 67) . Where cross-reactions had been reported with rabbit sera and were also observed with equine sera, they occurred at approximately the same level in relation to the homologous serum titer. Nineteen of the 52 major and minor cross-reactions found by HI with the equine sera have not been previously reported. At least 35 other cross-reactions, mostly minor ones, which have been reported at least once among rabbit sera were not found with the horse sera even after repeated testing with heated and unheated sera.
All but two of the 25 SN cross-reactions with equine sera had been found previously in rabbit antisera ( Table 5 ). Both of those were in antiserum type 30 which has been evaluated (in rabbits) three times (47, 58, 67) . Additional 65 SN cross-reactions, both major and minor, which had been reported for rabbit antisera were not found in the horse sera.
AV 32 AV 33 are recently described types, and no cross-typing information other than the original report (3) is available. Accordingly, rabbit antisera were prepared to confirm both the horse antisera data and the data of Blacklow et al. (3) . The rabbit antisera were prepared by three biweekly subcutaneous injections in Freund incomplete adjuvant (24) . Homologous and heterologous HI and SN titers of AV 32 and AV 33 rabbit antisera and AV 24 equine antiserum with all 33 serotypes are shown in Table 6 . The data with our rabbit antisera confirm the reciprocal high-level HI cross-reactions among types 24, 32, and 33, which were reported by Blacklow et al. (3) and which we found in the equine antisera (Table 2) table are defined as for   Tables 2 and 3 (see text) .
b, See Table 2 for HI titers and (36, 43, 48, 58) . With all of these sources of variation considered, the HI and SN titers listed in Tables 2 and 3 are genuine measurements of the antibody status of these sera. These titers (within one dilution either side of the mean) have been consistently found in tests with prototype strains and, although with more variation in titer, in tests with wild strains and current isolates.
Heat inactivation of equine antisera is not required for either HI or SN tests with prototype or currently isolated strains. Inactivation had no effect on homologous or heterologous titer or in "readability" of the test. This confirms our recent findings (25) , but remains in contrast to Zolotarskaya and Dreizin's report of high-titered, nonspecific HI inhibitors in horse sera (68) . We have also confirmed that kaolin is unnecessary for serum absorption in the HI test. Its use is also inadvisable since it may reduce antibody titers (25, 29, 65 Regardless of the cause of low or absent HI titers with these serotypes, such findings are the rule rather than the exception (36, 43, 53, 58) .
The SN titers determined by the 3-day test in MK compared well with those determined in our laboratory by a 7-day test in HEK microcultures. This supports the original findings of Rowe et al. in their use of the 3-day test in preference to a 7-day test in HeLa cells (48) . The ease of completing a neutralization test in so short a time has made the test in MK an indispensable tool in adenovirus research.
Comparing even in general terms the heterotypic responses found among the equine antisera with those found among rabbit antisera by a number of investigators is difficult. (36) . Other studies dealt with selected types, and often only one test procedure was used (3, 18, 23, 24, 33, 41, 45-48, 53, 59, 64, 66, 67) . In addition to variations in immunizing antigens, test procedures, interpretations, etc., rabbits may respond differently than horses to adenovirus immunization. In fact, some of the low-level (i.e., 10 or 20) heterologous titers among the equine antisera could be heterotypic anamnestic responses resulting from prior natural infection with unknown cross-reacting equine adenoviruses. Hence, random, low-level or even major crosses found only once or twice are perhaps more the response of an individual animal than a genuine cross-reaction. On the other hand, major or minor heterotypic titers which are repeatedly observed by many laboratories and with different animals (Tables 4 and 5 ) must be assumed to represent genuine antigenic relationships.
The reference equine antisera to adenovirus types 1 to 33 were prepared with a twofold purpose: to make available a stock of fully tested, type-specific antisera for definitive typing of isolates and detailed study of antigenic hybrids, and to serve as reference standards for the evaluation of other antisera prepared for routine use. In the present report, both of these objectives have been met.
